High Times
Home > Boards > Canadian > Medical - Drugs >

Biosyent Inc. (TSXV:RX)

Add TSXV:RX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 11/2/2016 3:04:39 PM - Followers: 18 - Board type: Free - Posts Today: 0


Stock Symbol: RX
Exchange: TSX Venture
Shares Outstanding: 12,521,195 
(as of 8/24/2011) 
Fully diluted: 14,315,825 (as of 12/31/2010)


BioSyent Inc. is a publicly traded life science company that acquires or licenses products and commercializes proprietary science-based technologies that advance human health and public safety (TSX Venture Exchange trading symbol - "RX").

BioSyent has embarked on a growth strategy to establish itself in Canada's pharmaceutical industry. BioSyent's focus is: sourcing pharmaceutical products that have been successfully developed and proven safe and effective; managing the regulatory process through to product registration (approval); and once approved, marketing these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to it.

In keeping with the above strategy, the Company has, through its subsidiary, BioSyent Pharma Inc. launched FeraMAX®, an oral hematinic, to the Canadian healthcare market. FeraMAX® is indicated for the prevention and treatment of iron deficiency anaemia (IDA). This non-ionic formulation leads to improved iron absorption by the body and eliminates adverse side effects normally associated with iron formulations. Shipments of FeraMAX® commenced in April 2007.

In 2008 BioSyent Pharma Inc. established a Hospital Products Division focused on licensing or acquiring pharmaceutical products used primarily in a hospital setting. The Hospital Products Division licensed its first product, Ciprofloxacin Injection, in the first quarter of 2008 and launched the product in the second quarter of 2008. Ciprofloxacin Injection, an antibacterial agent, is a generic equivalent to Cipro I.V. Minibags 2mg/ml from Bayer Inc.

In July 2009, the company through its subsidiary BioSyent Pharma Inc. signed an exclusive distribution agreement with a partner for an innovative topical anaesthetic product used in urology and gastroenterology. The product was approved by Health Canada in July, 2011.




The Company also manufactures and markets two products from its legacy business, namely Protect-It® and Insecolo™.

Protect-It® is a non-chemical, food-safe grain insecticide. The patented formula contains a natural mineral called diatomaceous earth ("DE"). Protect-It® was developed through collaborative research between the Winnipeg based Cereal Research Centre of Agriculture and Agri-Food Canada. Protect-It® is used as a preventative treatment against insect infestations in stored grains. It is registered for use in Canada, the United States, Croatia and Syria.

Insecolo is a natural insecticide for home and garden use made from a patented formula of DE and food grade additives. It is registered for use in Canada and is marketed by S.C. Johnson and Son Limited under the Raid® Earthblends™ Ant & Earwig Dust brand.



Management Profiles:

René C. Goehrum,
Chairman, President, Chief Executive Officer

René Goehrum is an experienced entrepreneur, leader and business builder. He has led businesses and teams at various stages of their development including start-ups, growth companies and mature products/businesses. His focus is on strategy, corporate and business development, and operations. Mr. Goehrum's career experience includes: Chariman, President and Chief Executive Officer of BioSyent Inc. (f.k.a. Hedley Technologies Inc.), a publicly Traded (TSXV-RX) specialty pharmaceutical company. President and co-founder of Bratch Goehrum Inc., a professional services firm that provided marketing and sales services to clients such as Procter & Gamble, Boehringer Ingelheim, Sandoz (n.k.a. Novartis), Kraft Foods, Coca Cola, H.J. Heinz Company and Canadian Imperial Bank of Commerce (CIBC). Progressive sales and product promotion assignments with Procter & Gamble Inc., a world leader in the development and marketing of consumer products. Mr. Goehrum's functional experience includes corporate strategy, sales and marketing strategy and execution, business operations and corporate finance.

Alfred D'Souza, Chief Financial Officer, Vice President Biosyent Inc.

Alfred D'Souza has been the Chief Financial Officer and Vice President of BioSyent Inc. since December 13, 2007. Mr. D'Souza joined BioSyent as Controller and Director of Finance in October 2006. Mr. D'Souza has over 25 years of accounting, finance and operations management experience in international businesses ranging from early stage to rapid growth to mature markets. Mr. D'Souza enjoyed a 16 year career with progressive management assignments at Colgate-Palmolive Company. Mr. D'Souza's last two positions at Colgate-Palmolive were Head of Finance (Country Controller) at Colgate-Palmolive Vietnam while it grew from sales of less than to USD $2 million to over $25 million, and most recently as Finance Director and Controller of Colgate-Palmolive India a publicly traded (BSE) USD $225 million company with 4,000 employees and 6 manufacturing plants in India. Mr. D'Souza is a Certified Management Accountant and M.B.A. from Wilfrid Laurier University. 

Douglas R. Larson, Director

Douglas R. Larson has considerable grain industry experience. Before August 1995, he served as President and CEO of James Richardson and Sons Ltd.-Grain Division. James Richardson and Sons is Canada's largest privately owned grain company. During the past forty years, Mr. Larson has served the grain industry in many capacities, including: President of Vancouver Grain Exchange; President of B.C. Terminal Elevators Operators' Association; a Director of the Canada Grains Council; Member of the Grain Elevators and Processors Society; Chairman of the Board of the Chamber of Maritime Commerce; a Member of the Board of Directors of Grain Insurance and Guarantee Company; Member of the Labour Canada Working Group for the Western Grain Elevator Industry; Member, Implementation Advisory Team, Agriculture Canada Grain and Oilseeds Branch.

Peter D. Lockhard, Director

Peter Lockhard is an entrepreneur and business leader with senior management, operations, sales/sales management, marketing and client service experience in the technology and marketing services industries. Mr. Lockhard, is a co-founder and principal of Aquiam Partners Ltd., a private corporation engaged in investment, acquisition, management and growth of entrepreneurial enterprises. After starting his career in public accounting and investment sales, Mr. Lockhard co-founded and served as President (1990-1998), of Between the I's a technology-based marketing services provider with clients such as Pepsi-Cola Canada, Bell Canada, Nortel and Labatt Breweries. Prior to founding Aquiam Partners, Mr. Lockhard served as a senior executive in several technology based businesses that served large multi-national clients such as Hewlett-Packard, Microsoft, Bank of Montreal, Barnes and Noble and American Airlines.

Milton E. Wakefield, Director

Milton Wakefield recently completed a ten-year term as Commissioner of the Canadian Grain Commission, the last seven as its Chief Commissioner. The Canadian Grain Commission is the regulatory agency responsible for maintaining grain quality standards and assessment in Canada. As its Chief Commissioner, Mr. Wakefield was responsible for advising the Minister of Agriculture on grain industry policies and regulations, and carrying the principal responsibility for promoting Canadian grain quality standards and management practices internationally. Mr. Wakefield has chaired several industry committees including the Western and Eastern Grain Standards Committees and was responsible for supervising the Winnipeg Commodity Exchange. During his tenure, Mr. Wakefield led several grain industry missions to Japan, the People's Republic of China, and several countries in South East Asia and Europe.



High Times
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RX News: BioSyent Announces Changes to Executive Management 09/10/2018 05:28:08 PM
RX News: BioSyent to Present at Upcoming Investor Conference 08/24/2018 12:00:00 PM
RX News: BioSyent Releases Q2 and H1 2018 Results 08/22/2018 08:00:00 AM
RX News: BioSyent Schedules Q2 2018 Earnings Release for August 22, 2018 08/10/2018 08:00:00 AM
RX News: BioSyent Releases Results for Q1 2018 05/30/2018 08:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#166   Volume seems to be drying up on RX.V rado 11/02/16 03:04:38 PM
#165   RX.V / BIOYF presentation MikeDDKing 04/12/16 03:29:57 PM
#164   BioSyent Releases Q4 and Full Year 2015 Results MikeDDKing 03/04/16 05:37:20 PM
#163   that .18 eps was for trailing 12 months. budge 08/21/14 04:25:10 PM
#162   BIOYF going nuts today. Nice earnings release. TrueFlaco 08/21/14 04:18:05 PM
#161   This is more than a 10 bagger from btmfdr2 10/28/13 04:30:53 PM
#160   Do you see now? eom zenvesting 10/28/13 11:52:53 AM
#159   BioSyent Pharma Signs Exclusive Licence and Distribution Agreement MikeDDKing 10/01/13 08:48:54 AM
#158   This isn't the venue to discuss stocks other MikeDDKing 09/07/13 01:39:52 PM
#157   Canadian insider is usually a few days behind. Kadillac 09/07/13 10:20:45 AM
#156   That looks wrong as there is no recent MikeDDKing 09/07/13 09:45:49 AM
#155   Interesting! ST Trader 09/07/13 09:42:21 AM
#154   Good day, people, sweet talker 09/04/13 10:58:51 AM
#153   I sold just enough today that I'm riding Fishin' Canuck 08/22/13 04:03:20 PM
#152   Yes! MikeDDKing 08/22/13 04:02:42 PM
#151   Nice close at 2.00 Fishin' Canuck 08/22/13 04:02:06 PM
#150   BioSyent is in with another great quarter. MikeDDKing 08/22/13 08:12:19 AM
#149   The statutory tax rate for them in Canada MikeDDKing 06/21/13 08:21:50 AM
#148   Hey Mike, do you have any idea what btmfdr2 06/20/13 11:04:40 PM
#147   It is looking good! MikeDDKing 06/10/13 09:47:58 PM
#146   RX.V $1.39 Getting close, just need ST Trader 06/10/13 07:08:06 PM
#145   BioSyent Pharma Launches New FeraMAX(R) Powder-Water Soluble Polysaccharide-I MikeDDKing 06/06/13 09:07:59 AM
#144   BioSyent Named to the PROFIT 500 Ranking of MikeDDKing 06/04/13 08:33:55 AM
#143   BioSyent Pharma Submits Two New Drugs to Health MikeDDKing 05/23/13 08:45:31 AM
#142   I like it! Fishin' Canuck 05/22/13 09:48:00 AM
#141   That is another excellent report for BIOYF / RX.V! MikeDDKing 05/22/13 08:57:55 AM
#140   BioSyent Releases First Quarter Results-Sales Increase 70%, Profit MikeDDKing 05/22/13 08:57:28 AM
#139   RX.V / BIOYF just continues to grow like clockwork. MikeDDKing 03/21/13 09:57:04 AM
#138   B: BioSyent Releases Full Year 2012 Results-Sales Increase gold80302 03/21/13 09:35:14 AM
#137   Trading on a stock like this depends upon MikeDDKing 02/25/13 09:24:32 AM
#136   Mike, thanks for bringing Biosyent to the Swing akmush 02/25/13 01:07:30 AM
#135   BioSyent Named to the 2013 TSX Venture Top MikeDDKing 02/14/13 08:54:10 AM
#134   BioSyent Presents at MicroCapClub Invitational MikeDDKing 02/12/13 09:39:52 AM
#133   RX.V / BIOYF did a presentation that I MikeDDKing 02/11/13 11:37:14 PM
#132   More insider buys for BIOYF/RX.V were posted. MikeDDKing 12/24/12 09:32:18 AM
#131   RX.V volume was 173,933. That is roughly MikeDDKing 11/15/12 04:04:57 PM
#130   That was a very nice quarter for BIOYF MikeDDKing 11/15/12 08:23:27 AM
#129   BioSyent Releases Third Quarter Results; Record Quarterly Sales MikeDDKing 11/15/12 08:19:40 AM
#128   I forgot to post this here, but this MikeDDKing 10/18/12 02:21:43 PM
#127   I'm surprised there isn't more chatter on BioSyent MikeDDKing 10/18/12 02:19:52 PM
#126   Things have really quieted down - with both btmfdr2 10/18/12 02:12:52 PM
#125   There is a web site for Cathejell Jelly 2%: MikeDDKing 10/10/12 09:28:14 AM
#124   By my count, 1,709,300 shares have traded under MikeDDKing 09/29/12 10:33:16 AM
#123   There were more insider buys on RX.V / MikeDDKing 09/20/12 01:55:48 PM
#122   There were more insider purchases of RX.V / MikeDDKing 09/04/12 10:51:00 AM
#121   BIOYF / RX.V has had two days of MikeDDKing 08/31/12 04:11:18 PM
#120   Nice report! MikeDDKing 08/22/12 09:38:15 PM
#119   Looks like .03 Mike, just like you thought. ST Trader 08/22/12 05:35:24 PM
#118   Yes MikeDDKing 08/21/12 12:39:15 PM
#117   It sounds like these products have unique charachteristics btmfdr 08/21/12 12:33:40 PM